C Diff Treatment

For Taiwanese adults with CDI, the failure rate of metronidazole therapy approached 50%, which suggests the reappraisal of the therapeutic role of metronidazole therapy, especially for patients with leukocytosis or underlying congestive heart failure.

AGA’s Clostridioides difficile video is available in Spanish to help patients learn about C. diff infection symptoms and treatment.

Frequent recurrence of Clostridioides difficile infection drives up financial burdens of the disease and underscores the need to improve access to treatment, infection prevention, and new therapies.

Before she finally had successful treatment for her Clostridioides difficile infection in New Haven, Connecticut, Freda Pyles’ family physician in rural Pennsylvania was terrified and frustrated that he could not cure her and other patients.

Background Clostridiodies difficile infection (CDI) has been characterized by the Center for Disease Control and Prevention (CDC) as an urgent public health threat and a major concern in hospital, outpatient and extended-care facilities worldwide. Methods A retrospective cohort study of patients aged ≥ 18 hospitalized with CDI in New York State (NYS) between January 1, 2014–December 31, 2016. Data were extracted from NY Statewide Planning and Research Cooperative (SPARCS) and propensity score matching was performed to achieve comparability of the CDI (exposure) and non-CDI (non-exposure) groups. Of the 3,714,486 hospitalizations, 28,874 incidence CDI cases were successfully matched to 28,874 non-exposures. Results The matched pairs comparison demonstrated that CDI cases were more likely to be readmitted to the hospital at 30 (28.26% vs. 19.46%), 60 (37.65% vs. 26.02%), 90 (42.93% vs. 30.43) and 120 days (46.47% vs. 33.74), had greater mortality rates at 7 (3.68% vs. 2.0%) and 180 days (20.54% vs. 11.96%), with significant increases in length of stay and total hospital charges (p

Implementation of the CDI treatment pathway was associated with better clinical outcomes and hospital cost savings. The findings help validate real-world value of fidaxomicin for CDI disease management.

This inflammation of the colon poses a substantial burden to patients and the health care system.

CDI is associated with a large burden on patients and health care systems, significantly increasing hospital utilization, costs and mortality.

Clostridioides difficile infection is a highly contagious disease that affects 500,000 people in the U.S. and results in nearly 30,000 deaths per year.

“Since I wrote the first edition of the book nearly a decade ago, a number of important discoveries have improved our management of C. diff,” Lamont said.

Ulcerative colitis is a chronic debilitating inflammatory bowel disease with no curative treatment currently available. INRAE scientists have developed a novel predictive model of disease progression in pediatric patients that integrates both gut microbiota and host inflammation data.

Are Vancomycin Non-Susceptible Clostridioides difficile Strains Emerging?

AI and machine learning have been in use for the past decade and, since then, have acted as our primary modus for attaining trending data in health care facilities.

AbstractBackground. Debilitating symptoms of recurrent Clostridioides difficile infection (rCDI) often lead to long-term effects on health-related quality-of-li

Take 5 minutes to catch up on Infection Control Today’s highlights for the week ending July 8.

Objectives: Clostridioides difficile infection (CDI) is the leading cause of healthcare-associated diarrhea, often complicated by severe infection and recurrence with increased morbidity and mortality. Data from large cohorts in Switzerland are scarce. We aimed to describe diagnostic a …

Cdiff32 is a valid, reliable, and responsive disease-specific HRQOL questionnaire fit-for-purpose for interventional treatment trials. The significant improvement in non-recurrent patients by 8 weeks demonstrates the negative impact of rCDI on HRQOL.

CDIs among patients with UC receiving tofacitinib were infrequent, cases were mild-moderate in severity, and most resolved with treatment.

Pharmacy Times spoke with Paul Feuerstadt, MD, FACG, AGAF, about the investigative C. difficile treatment RBX2660.

Our study confirmed that the increase in the abundance of beneficial bacteria such as Bifidobacteriaceae, and Christensenellaceae were prominently evident during recovery after administration of a high dose of cholecalciferol. These findings indicate that vitamin D administration may b …

Paul Feuerstadt, MD, FACG, AGAF, discussed the investigative C. difficile treatment RBX2660 and how it impacts time to recurrence.

Letter to the Editor: Extraintestinal Clostridioides difficile Abscess after Synchronous Colon and Liver Resection

The pathogenic Clostridioides difficile and Clostridium perfringens are responsible for many health care-associated infections as well as systemic and enteric diseases. Therefore, they represent a major health threat to both humans and animals. Concerns regarding increasing antibiotic …

Clostridioides difficile Treatment While Breastfeeding

First described in the 4th Century in China, practiced since the 1950’s and re-discovered relatively recently [1][2], Fecal Microbiota Transplantation (FMT) or simply Fecal Transplant is a therapeutic approach in which more or less processed [...]

Preethi Venkat, MD, second-year internal medicine resident at the University of California, San Diego, discusses differences in hospitalizations for patients with IBD and Clostridiodes difficile (C. diff) infection vs those with IBD hospitalized for other reasons.